Life sciences software & AI news

Showing 1000+ results

Oct 20, 2026

Pulse Equity: The Healthcare Robots and Gix Internet Aims to Transform Critical Deliveries in Hospitals with AI-Powered Autonomous Systems

HONG KONG, Oct. 20, 2026 /PRNewswire/ -- GIX Internet Ltd. (NASDAQ: GIXI) (TASE: GIX) ("GIX" or the "Company") is an Israeli dual-listed technology company focused on "Physical AI": applying intelligence so that robots, people and goods move more reliably and efficiently in real operating environments. Through its wholly owned subsidiary Deliverz.AI, the Company is developing an AI orchestration platform intended to manage the movement of robots, people and goods within an operational site. The

Oct 20, 2026

Press release

Myllia Biotechnology Appoints Board with Industry Leaders

Single-cell commercial leader Simone Günther, US biotechveteran Sandy Zweifach, and Werner Lanthaler (Wlanholding) join to guideMyllia's next phase of growthVienna, Austria – October 8, 2026 – MylliaBiotechnology, a specialist in high-content CRISPR screens in primary humancells, today announced the formation of its Board. The new governance body willoversee and advise Myllia's management team, led by co-founders Dr. ThomasMoser (CEO) and Dr. Tilmann Buerckstuemmer (CSO). The Board comprises San

Oct 20, 2026

Press release

Trinity Acquires Verix, Adding AI-Powered Next-Best-Action and Omnichannel Orchestration to the TrinityEDGE Platform

Verix's patented Tovana™ platform and its full team join Trinity, extending TrinityEDGE™ from what commercial teams know into what they do nextWALTHAM, Mass., Oct. 20, 2026 /PRNewswire/ -- Trinity, the leader in integrating human and artificial intelligence for life sciences commercialization, today announced it has acquired Verix, the pharma-native commercial intelligence company behind the patented, AI-powered Tovana™ platform. Tovana is live today in global pharma, biotech, and specialty phar

A close-up of a tumor sample in a petri dish on a lab bench

Oct 20, 2026

‘A two-way conversation with the tumor’: Researchers use ‘avatar’ to predict immunotherapy responses

Researchers at Elephas Biosciences are pioneering a novel approach to predict immunotherapy responses by creating a tumor "avatar" from patient biopsies.In collaboration with various academic institutions, Elephas has utilized 124 tumor samples to develop an algorithmic model that assesses how these samples respond to different immunotherapies, including anti-PD-L1 and anti-CTLA-4 treatments. This model measures responses through cytokines, which indicate whether the immune system is mounting an

Oct 20, 2026

Press release

Azra AI Acquires Blackford Analysis to Close the Most Dangerous Gap in Healthcare: What Happens After the Scan

One platform now carries every imaging finding from the first scan to completed care, ending the era of AI flags that go nowhereNASHVILLE, Tenn., Oct. 20, 2026 /PRNewswire/ -- Every day, scans reveal signs of cancer, heart disease, and other serious illnesses that never turn into care. Azra AI, the industry-leading end-to-end enterprise platform that identifies patients who need care in real time and manages their journey from early suspicion through survivorship, today announced it has complete

An open appointment book on a desk in a dimly lit office, with a calendar and wall clock in the background.

Oct 20, 2026

VA launches real-time external scheduling

The Department of Veterans Affairs has introduced a new tool aimed at streamlining the scheduling of external appointments for veterans, enhancing the efficiency of care coordination.The External Provider Scheduling (EPS) system, developed in collaboration with Epic Systems and WellHive, allows VA care teams to easily search for, book, and track appointments with outside healthcare providers. This system is designed to integrate seamlessly with any external provider organization, giving VA staff

Oct 20, 2026

Press release

PrecisePK Marks 40+ Years of Precision Dosing, Highlights EHR Integrations Driving Safer Pharmacist Workflows

Celebrating four decades of precision dosing, PrecisePK connects directly to Epic, Cerner, and Sentri7 so patient data comes to clinicians and more time goes to patient care.SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- PrecisePK, a therapeutic drug monitoring (TDM) software company used by hospital systems worldwide, is highlighting its electronic health record (EHR) and clinical surveillance integrations this year, building on more than 40 years of precision dosing experience since launching from U

Oct 20, 2026

Press release

New Platform Creates PhD-level Experts in Drug Development in Mere Days

Inovia Bio's AI-powered "Falcon" cuts months of work from drug development to hours LONDON, Oct. 20, 2026 /PRNewswire/ -- Inovia Bio, an AI company that accelerates drug development for pharmaceutical and lean biotech organizations, today announced the launch of Inovia Falcon Workflows (Falcon), an end-to-end AI system that completes advanced drug development work in hours. Inovia can now build new PhD-level AI employees in days, giving drug developers more expert capacity while their teams stay

Oct 20, 2026

Press release

ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics

CAMBRIDGE, England--(BUSINESS WIRE)--ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi (EURONEXT: SAN) (NASDAQ: SNY) to develop and commercialize extended exposure ver

Minimalist heart silhouette with pulse line

Oct 20, 2026

Circle CVI joins EXIT-CVD research consortium to advance

Circle Cardiovascular Imaging (Circle CVI) has joined the EXIT-CVD consortium, a significant five-year initiative aimed at revolutionizing cardiovascular care. This collaboration involves 42 partners from 17 countries and is set to conduct 22 clinical studies with over 14,000 patients, focusing on early detection and personalized interventions to improve patient outcomes.The EXIT-CVD project, co-funded by the European Union's Innovative Health Initiative, aims to transform how cardiovascular dis

Oct 20, 2026

Press release

Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026

Research reinforces the significance of genomic and epigenomic profiling approaches to characterize tumor types, identify biomarkers, and support risk stratificationPresentations reflect Guardant’s strong biopharma and academic collaborations, along with public-private partnerships in EuropePALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—includin

Oct 20, 2026

Press release

Flatiron Health Announces Research at ESMO Congress 2026 Examining Cancer Treatment and Outcomes Across Global Markets

Seventeen abstracts feature Flatiron data, including four studies exploring international treatment patterns, real-world treatment effectiveness, and opportunities to address gaps in colorectal, lung, and prostate cancer careNEW YORK--(BUSINESS WIRE)--Flatiron Health today announced that four research abstracts will be presented as e-posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. The research examines how cancer treatments

Back to start
Previous
Page 33 of 84
Next

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Platform

Domains

Services

Legal